## François Maltais

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5654661/publications.pdf

Version: 2024-02-01

56 papers 7,320 citations

218592 26 h-index 53 g-index

56 all docs 56
docs citations

56 times ranked 5907 citing authors

#	Article	IF	CITATIONS
1	Home-based Pulmonary Rehabilitation is Effective in Frail COPD Patients with Chronic Respiratory Failure. Chronic Obstructive Pulmonary Diseases (Miami, Fla ), 2022, 9, 15-25.	0.5	7
2	Physical and affective components of dyspnoea are improved by pulmonary rehabilitation in COPD. BMJ Open Respiratory Research, 2022, 9, e001160.	1.2	7
3	Impaired Ventilatory Efficiency, Dyspnea, and Exercise Intolerance in Chronic Obstructive Pulmonary Disease: Results from the CanCOLD Study. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1391-1402.	2.5	19
4	Ambient Air Pollution and Dysanapsis: Associations with Lung Function and Chronic Obstructive Pulmonary Disease in the Canadian Cohort Obstructive Lung Disease Study. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 44-55.	2.5	24
5	The Null Q0 <sub>Ourém</sub> Variant within a Copy-Neutral Loss-of-Heterozygosity Event Causing Alpha-1 Antitrypsin Deficiency. American Journal of Respiratory Cell and Molecular Biology, 2022, 66, 700-702.	1.4	O
6	Applying key learnings from the EMAX trial to clinical practice and future trial design in COPD. Respiratory Medicine, 2022, , 106918.	1.3	O
7	The Prevalence of Chronic Obstructive Pulmonary Disease (COPD) and the Heterogeneity of Risk Factors in the Canadian Population: Results from the Canadian Obstructive Lung Disease (COLD) Study. International Journal of COPD, 2021, Volume 16, 305-320.	0.9	16
8	Physical Frailty in COPD Patients with Chronic Respiratory Failure. International Journal of COPD, 2021, Volume 16, 1381-1392.	0.9	18
9	Treatment of COPD with Long-Acting Bronchodilators: Association Between Early and Longer-Term Clinically Important Improvement. International Journal of COPD, 2021, Volume 16, 1215-1226.	0.9	8
10	Update on Asthma–COPD Overlap (ACO): A Narrative Review. International Journal of COPD, 2021, Volume 16, 1783-1799.	0.9	46
11	Dual Bronchodilator Therapy as First-Line Treatment in Maintenance-NaÃ-ve Patients with Symptomatic COPD: A Pre-Specified Analysis of the EMAX Trial. International Journal of COPD, 2021, Volume 16, 1939-1956.	0.9	6
12	Exploring PI3Kl̂ Molecular Pathways in Stable COPD and Following an Acute Exacerbation, Two Randomized Controlled Trials. International Journal of COPD, 2021, Volume 16, 1621-1636.	0.9	13
13	Efficacy and Safety of Umeclidinium/Vilanterol in Current and Former Smokers with COPD: A Prespecified Analysis of The EMAX Trial. Advances in Therapy, 2021, 38, 4815-4835.	1.3	4
14	Significance of Stenotrophomonas maltophilia When Detected in Sputum of Ambulatory Patients with COPD. International Journal of COPD, 2021, Volume 16, 2895-2900.	0.9	4
15	Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model. International Journal of COPD, 2021, Volume 16, 3105-3118.	0.9	2
16	Effect of once-daily fluticasone furoate/vilanterol <i>versus</i> vilanterol alone on bone mineral density in patients with COPD: a randomized, controlled trial. Therapeutic Advances in Respiratory Disease, 2020, 14, 175346662096514.	1.0	2
17	Relieving exertional dyspnea during the 3-min constant speed shuttle test in patients with COPD with indacaterol/glycopyrronium <i>versus</i> tiotropium: the RED trial. Therapeutic Advances in Respiratory Disease, 2020, 14, 175346662093950.	1.0	4
18	<p>Long-Term Effectiveness of a Home-Based Pulmonary Rehabilitation in Older People with Chronic Obstructive Pulmonary Disease: A Retrospective Study</p> . International Journal of COPD, 2020, Volume 15, 2505-2514.	0.9	7

#	Article	IF	Citations
19	Lung cancer resection and postoperative outcomes in COPD: A single-center experience. Chronic Respiratory Disease, 2020, 17, 147997312092543.	1.0	14
20	Comparative measurement properties of constant work rate cycling and the endurance shuttle walking test in COPD: the TORRACTO <sup><math>\hat{A}^{\otimes}</math></sup> clinical trial. Therapeutic Advances in Respiratory Disease, 2020, 14, 175346662092685.	1.0	4
21	Identification and definition of asthma–COPD overlap: The CanCOLD study. Respirology, 2020, 25, 836-849.	1.3	45
22	Metabolic profiles among COPD and controls in the CanCOLD population-based cohort. PLoS ONE, 2020, 15, e0231072.	1.1	4
23	Cardiovascular Risk in COPD. Chest, 2020, 157, 753-754.	0.4	5
24	Common pathophysiological pathways of the autonomic nervous system. , 2020, , 12-30.		0
25	Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial. Respiratory Research, 2019, 20, 238.	1.4	81
26	Canadian Thoracic Society Clinical Practice Guideline on pharmacotherapy in patients with COPD – 2019 update of evidence. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2019, 3, 210-232.	0.2	43
27	Dual bronchodilation with tiotropium/olodaterol further reduces activity-related breathlessness <i>versus</i> tiotropium alone in COPD. European Respiratory Journal, 2019, 53, 1802049.	3.1	30
28	Longitudinal comparison of outcomes in patients with smoking-related asthma-COPD overlap and in non-smoking asthmatics with incomplete reversibility of airway obstruction $\langle p \rangle$ . International Journal of COPD, 2019, Volume 14, 493-498.	0.9	6
29	Inter-day test–retest reliability and feasibility of isokinetic, isometric, and isotonic measurements to assess quadriceps endurance in people with chronic obstructive pulmonary disease: A multicenter study. Chronic Respiratory Disease, 2019, 16, 147997311881649.	1.0	22
30	<p>Low Liver Density Is Linked to Cardiovascular Comorbidity in COPD: An ECLIPSE Cohort Analysis</p> . International Journal of COPD, 2019, Volume 14, 3053-3061.	0.9	2
31	Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease. Therapeutic Advances in Respiratory Disease, 2018, 12, 175346581875509.	1.0	29
32	Asthma-COPD Overlap Phenotypes and Smoking :Comparative features of asthma in smoking or non-smoking patients with an incomplete reversibility of airway obstruction. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2018, 15, 130-138.	0.7	21
33	Ectopic adiposity and cardiometabolic health in COPD. International Journal of COPD, 2018, Volume 13, 3331-3340.	0.9	16
34	Functional Tests in Chronic Obstructive Pulmonary Disease, Part 1: Clinical Relevance and Links to the International Classification of Functioning, Disability, and Health. Annals of the American Thoracic Society, 2017, 14, 778-784.	1.5	52
35	Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD. European Respiratory Journal, 2017, 49, 1601348.	3.1	64
36	Ectopic fat accumulation in patients with COPD: an ECLIPSE substudy. International Journal of COPD, 2017, Volume 12, 451-460.	0.9	33

#	Article	IF	Citations
37	Use of exercise testing in the evaluation of interventional efficacy: an official ERS statement. European Respiratory Journal, 2016, 47, 429-460.	3.1	311
38	Undiagnosed Chronic Obstructive Pulmonary Disease Contributes to the Burden of Health Care Use. Data from the CanCOLD Study. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 285-298.	2.5	110
39	Findings on Thoracic Computed Tomography Scans and Respiratory Outcomes in Persons with and without Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study. PLoS ONE, 2016, 11, e0166745.	1.1	63
40	Prospective validation of the endurance shuttle walking test in the context of bronchodilation in COPD. European Respiratory Journal, 2014, 44, 1166-1176.	3.1	13
41	Canadian Cohort Obstructive Lung Disease (CanCOLD): Fulfilling the Need for Longitudinal Observational Studies in COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2014, 11, 125-132.	0.7	122
42	Effects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trials. Therapeutic Advances in Respiratory Disease, 2014, 8, 169-181.	1.0	65
43	Quality Assurance of Spirometry in a Population-Based Study –Predictors of Good Outcome in Spirometry Testing. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2014, 11, 143-151.	0.7	23
44	An Official American Thoracic Society/European Respiratory Society Statement: Key Concepts and Advances in Pulmonary Rehabilitation. American Journal of Respiratory and Critical Care Medicine, 2013, 188, e13-e64.	2.5	2,668
45	Responsiveness of Various Exercise-Testing Protocols to Therapeutic Interventions in COPD. Pulmonary Medicine, 2013, 2013, 1-11.	0.5	56
46	Decline of Resting Inspiratory Capacity in COPD. Chest, 2012, 141, 753-762.	0.4	150
47	Detecting Improvements in Dyspnea in COPD Using a Three-Minute Constant Rate Shuttle Walking Protocol. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2012, 9, 395-400.	0.7	18
48	Fatigue in COPD: Prevalence and effect on outcomes in pulmonary rehabilitation. Chronic Respiratory Disease, 2011, 8, 119-128.	1.0	46
49	Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respiratory Medicine, 2011, 105, 580-587.	1.3	96
50	The impact of obesity on walking and cycling performance and response to pulmonary rehabilitation in COPD. BMC Pulmonary Medicine, 2010, 10, 55.	0.8	71
51	Paced-Walk and Step Tests to Assess Exertional Dyspnea in COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2009, 6, 330-339.	0.7	33
52	Effects of Home-Based Pulmonary Rehabilitation in Patients with Chronic Obstructive Pulmonary Disease. Annals of Internal Medicine, 2008, 149, 869.	2.0	323
53	Canadian Thoracic Society Recommendations for Management of Chronic Obstructive Pulmonary Disease – 2007 Update. Canadian Respiratory Journal, 2007, 14, 5B-32B.	0.8	415
54	American Thoracic Society/European Respiratory Society Statement on Pulmonary Rehabilitation. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 1390-1413.	2.5	1,644

#	Article	IF	CITATIONS
55	The Metabolic Syndrome in Patients With Chronic Obstructive Pulmonary Disease. Journal of Cardiopulmonary Rehabilitation and Prevention, 2005, 25, 226-232.	0.5	144
56	Improvements in Symptom-Limited Exercise Performance Over 8 h With Once-Daily Tiotropium in Patients With COPD. Chest, 2005, 128, 1168-1178.	0.4	291